FORT LAUDERDALE, Fla., March 19, 2026 (GLOBE NEWSWIRE) — Kaida BioPharma, a biotechnology firm growing focused therapies for girls with hard-to-treat gynecologic cancers, in the present day introduced its govt management crew and board. Every member brings many years of expertise in biotechnology, medical growth, regulatory technique, manufacturing, finance, and commercialization to assist advance Kaida’s lead product candidate, KAD-101, towards first-in-human medical analysis. The corporate is growing KAD-101 for recurrent ovarian most cancers, the place remedy choices slender shortly and sturdy management stays restricted.
Kaida BioPharma is constructing KAD-101, a next-generation prolactin receptor antagonist for the ovarian most cancers hole, the house the place sufferers are too usually left biking via remedy with too few sturdy choices.
Along with her position as Chairperson of the Board, Kaida founder Dr. Stella Vnook has been named Performing Chief Govt Officer. Dr. Vnook is an completed biotechnology founder, govt, and advisor with in depth expertise guiding early-stage therapeutics from scientific basis via capital formation. At Kaida, she leads company technique, growth planning, and investor engagement.
“The science brought me here, and the women out there still fighting are why I stay. At Kaida, we are building for the ovarian cancer gap, for patients whose options narrow too fast and whose disease still outpaces available therapies,” stated Dr. Vnook. “By targeting the survival signals that keep these tumors alive, we believe KAD-101 has the potential to help overcome treatment resistance and create a new path toward more durable control. More options mean more time, and more time means everything.”
Craig Pierson, a founder alongside Dr. Vnook, has been appointed Director at Kaida BioPharma. Mr. Pierson is a life sciences investor and firm builder with greater than 25 years of expertise in funding banking and personal capital formation. He offers strategic oversight and financing experience.
More Read
George E. Peoples, MD, FACS has been appointed fractional Chief Medical Officer. Dr. Peoples is a surgical oncologist with many years of expertise in translational oncology and medical growth. He’s additionally the founding father of the Most cancers Vaccine Improvement Program, Most cancers Perception, and LumaBridge. At Kaida, he helps information medical technique and IND planning.
John Langenheim, PhD has been appointed fractional Chief Scientific Officer. Dr. Langenheim is a molecular biologist with greater than 20 years of expertise in therapeutic protein design and preclinical growth. His scientific management has been instrumental in advancing KAD-101 towards medical analysis.
Pamela Swiggard has been appointed Head of Regulatory Affairs. She is a pharmaceutical govt with prior expertise at corporations together with Pfizer and Endo Prescribed drugs. She brings deep experience throughout the product lifecycle, from growth via regulatory approval and commercialization. At Kaida, she leads regulatory technique and FDA engagement in help of IND readiness for KAD-101.
More Read
Eric Hacherl, PhD has been appointed Head of Manufacturing. Dr. Hacherl is a senior pharmaceutical operations chief with greater than 25 years of expertise in biologics manufacturing, cGMP compliance, and course of growth. At Kaida, he’s chargeable for serving to guarantee medical provide readiness for KAD-101.
Mark Sales space has been appointed Chief Industrial Officer. Mr. Sales space is a seasoned pharmaceutical and biotechnology govt with greater than 25 years of expertise constructing business methods for oncology and uncommon illness merchandise. His background contains management throughout launch planning, model technique, entry, and market growth for necessary oncology merchandise, together with EMEND, EMEND IV, Zolinza, vintafolide, KEYTRUDA, and the avutometinib plus defactinib mixture for low grade serous ovarian most cancers. At Kaida, he’s chargeable for business technique for KAD-101, together with positioning, market growth, and long-term entry planning.
About Kaida BioPharma
Kaida BioPharma is a biopharmaceutical firm growing focused therapies for hormone-driven gynecologic cancers. Its lead candidate, KAD-101, is a prolactin receptor antagonist being developed for recurrent ovarian most cancers, the place remedy choices slender shortly and plenty of sufferers nonetheless face restricted sturdy management. Kaida is targeted on constructing revolutionary therapies for sufferers left within the ovarian most cancers hole and in different areas of excessive unmet want. For extra data, go to kaida-biopharma.com.
